Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Learn more ...

As part of this partnership, AMD made a $20 million strategic investment in Absci. This collaboration supports our mission of creating better biologics faster by offering optimized compute ...

The company also announced a collaboration with chipmaker AMD to power its advanced de novo AI antibody design models, as well as AI biotechnology company Owkin to co-develop therapeutic candidates ...

Absci Corp's collaboration with AMD provides optimized compute solutions, enhancing performance and reducing costs for complex biological modeling. The company demonstrated significant ...

VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results ...

VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be ...

Absci Corporation (NASDAQ:ABSI) saw its shares drop 7.4% after the AI-driven drug discovery company reported fourth quarter revenue that missed analyst expectations. The company posted revenue of $0.7 ...

Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Absci continues to focus its ...

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...